~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with ...

Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company with a market capitalization of $183 million, announced today that their partner, Norgine Pharmaceuticals Ltd., has launched PEDMARQSI ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

This requires a conical flask and gas syringe. Sodium thiosulfate reacts with dilute hydrochloric acid to produce sodium chloride, water, sulfur dioxide and sulfur. The sulfur makes the solution ...

Draft guidance from Nice recommends Pedmarqsi, also known as anhydrous sodium thiosulfate – which is made by Norgine, for children undergoing this form of chemotherapy aged one month to 17 years ...